IGF1 and prostate carcinoma: In preclinical studies, the use of the antidiabetic drug metformin has been postulated to affect prostate cancer development and progression in multiple ways: through AMPK-dependent and -independent mechanisms, changing activity in the IGF-1 signaling pathway, suppressing the androgen receptor pathway, inhibiting the mTOR pathway, as well as impacting on lipogenesis [17].